Eli Lilly licenses ADDF's SpeechDx dataset for Alzheimer's research

The Alzheimer's Drug Discovery Foundation said Eli Lilly has licensed SpeechDx, a longitudinal speech-and-biomarker dataset for Alzheimer's research. Lilly is the third licensee after Siemens Healthineers and Callyope; the study follows 2,650 participants with quarterly speech data collected over three years.

• SpeechDx covers 2,650 participants with quarterly data collection over three years
• Lilly is the third licensee of the dataset after Siemens Healthineers and Callyope
• ADDF has put $150M into its Diagnostics Accelerator, including a new $50M tranche
• Data is collected in English, Spanish and Catalan at clinical sites worldwide